TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03808389

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Donor FMT
Description: Fecal microbiota transplantation through nasojejunal administration. Fecal matter will be collected prior to the start of the study from healthy donors and will be frozen at -80°C after thorough screening for infectious diseases. At the time of transplantation, samples will be thawed and administrated to the patients in the treatment group.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Autologous FMT
Description: Fecal microbiota transplantation through nasojejunal administration. Fecal matter will be collected prior to the start of the study from each patient and will be frozen at -80°C after thorough screening for infectious diseases. At the time of transplantation, samples will be thawed and administrated to the patients in the control group.
Study: NCT06374472

Intervention type: PROCEDURE
Intervention: Osteosynthesis
Description: Some patients had osteosynthesis using a long construct, others had osteosynthesis using a short construct. Short constructs designated constructs only taking one level above and one level below the injury level (the fractured vertebra was not always included in the construct). The montages taking more than one level above or below the lesion were considered to be a long montage. Osteosynthesis is carried out using Cotrel Dubousset type rods and screws.
Study: NCT03135171

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: All dose levels will receive 8 mg/kg loading dose for cycle 1, followed by 6 mg/kg in subsequent cycles, every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Dose Levels two and three will receive 840 mg loading dose for cycle 1, followed by 420 mg in subsequent cycles, every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab 4-8 mg/kg, administered intravenously every three weeks
Study: NCT04098042

Intervention type: DEVICE
Intervention: Scaffold
Description: implantation of a Magmaris scaffold
Study: NCT04349163

Intervention type: OTHER
Intervention: Questionnaire
Description: CD-RISC 25 questionnaire
Study: NCT05590936

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dimenhydrinate Tablets
Description: 2 hours preoperative per os administration of 50 mg dimenhydrinate

Intervention type: DRUG
Group type: OTHER
Intervention: Ondansetron iv
Description: Intraoperative intravenous administration of 4 mg ondansetron
Study: NCT03875209

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 10E8.4/iMab
Description: bispecific monoclonal antibody

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 10E8.4/iMab
Description: bispecific monoclonal antibody

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 10E8.4/iMab
Description: bispecific monoclonal antibody

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 10E8.4/iMab
Description: bispecific monoclonal antibody
Study: NCT02094963

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: 180mg loading and 90mg bid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: 600mg loading and 75mg qd
Study: NCT03926754

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mirabegron
Description: Study A The maximum tolerated dose up to a maximum of 300 mg per day for 26 weeks.~Study B One single dose of 300 mg at day one followed by 150 mg x 2 for 1 week (8-11 days).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mirabegron
Description: Study A The maximum tolerated dose up to a maximum of 300 mg per day for 26 weeks.~Study B One single dose of 300 mg at day one followed by 150 mg x 2 for 1 week (8-11 days).
Study: NCT01764971

Intervention type: OTHER
Intervention: IQ assessment and visual- motor assessment
Description: Psychological examination and evaluation for both groups to diagnose those with behavioral and /or cognitive dysfunction.

Intervention type: OTHER
Intervention: IQ assessment and visual- motor assessment
Description: Psychological examination and evaluation for both groups to diagnose those with behavioral and /or cognitive dysfunction.

Intervention type: OTHER
Intervention: EEG,brain imaging
Description: For patients with cognitive or behavioral deficit, MRI brain and quantitative EEG will be done to identify any CNS abnormality.
Study: NCT00800683

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1356
Description: BI 1356 dosed once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo matching BI 1356 taken once daily
Study: NCT00990054

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plerixafor
Description: 240 mcg/kg/dose and proceeding to escalating dose levels for determination of the single-dose maximum tolerated dose (MTD) provided that there are no unacceptable dose limiting toxicities
Study: NCT01848353

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: All participants will perform exercise training at the wellness center. Exercise duration and intensity will be recorded with heart rate monitors.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: All participants will perform exercise training at the wellness center. Exercise duration and intensity will be recorded with heart rate monitors.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: All participants will perform exercise training at the wellness center. Exercise duration and intensity will be recorded with heart rate monitors.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise training
Description: All participants will perform exercise training at the wellness center. Exercise duration and intensity will be recorded with heart rate monitors.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise training
Description: All participants will perform exercise training at the wellness center. Exercise duration and intensity will be recorded with heart rate monitors.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise training
Description: All participants will perform exercise training at the wellness center. Exercise duration and intensity will be recorded with heart rate monitors.
Study: NCT01624987

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NET for Forensic Offender Rehabilitation (FORNET): a variant of Narrative Exposure Therapy
Description: During the proposed therapy, the client constructs a chronological narrative of his or her whole life which includes all traumatic experiences and perpetrated violent acts. All emotions, cognitions, sensory information, and physiological reactions are activated and linked to the autobiographical context.In five sessions the trained therapist and the client try to go through all important traumatic experiences and perpetrated violent acts. The sixth session is a group session with four to five clients. The group session is oriented on Interpersonal Psychotherapy and focuses on the role change from soldier to civilian.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control group
Description: The control group receives no intervention.
Study: NCT03229408

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salsalate
Description: Lean PCOS Arms: Salsalate 1.5 gm PO bid; Obese PCOS Arm: Salsalate 2.0 gm PO bid
Study: NCT01764906

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Iliac crest bone graft
Study: NCT05471466

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical incision
Description: Surgical incisions to the neck as part of the management of the head and neck condition.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical incision
Description: Surgical incisions to the neck as part of the management of the head and neck condition.
Study: NCT03229408

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salsalate
Description: Lean PCOS Arms: Salsalate 1.5 gm PO bid; Obese PCOS Arm: Salsalate 2.0 gm PO bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salsalate
Description: Lean PCOS Arms: Salsalate 1.5 gm PO bid; Obese PCOS Arm: Salsalate 2.0 gm PO bid
Study: NCT02364570

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Glucose (100g)
Description: Ingestion of glucose (100g)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucose (75g)
Description: Ingestion of glucose (75g)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucose (75g)
Description: Ingestion of glucose (75g)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucose (75g)
Description: Ingestion of glucose (75g)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole Eggs
Description: Ingestion of 1.5 whole eggs

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Egg Whites
Description: Ingestion of 7 egg whites

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Egg Yolks
Description: Ingestion of 2 egg yolks
Study: NCT03052075

Intervention type: OTHER
Intervention: Retrospective Data Review
Description: Retrospective, uncontrolled pre- and post-test design in a case series of approximately 250 patients who underwent parathyroidectomy at MD Anderson Cancer Center (years 1990 - 2013 ) and had bone density measures recorded at baseline and at one year post-surgery. Data extracted from the surgical oncology database for bone mineral density measures for each patient at multiple sites including the lumbar spine, total hip (right/left), femoral neck (right/left), and distal 1/3 radius. All measures recorded from two time points: presurgical (baseline) and postsurgical (all follow-up available dates beginning at 1 year post-parathyroidectomy).
Study: NCT02395081

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: 600 IU Vitamin D3 in prenatal vitamin
Description: Women will receive 600 IU 25(OH)D in prenatal vitamin.
Study: NCT03229408

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Appears identical to experimental drug

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Appears identical to experimental drug

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Appears identical to experimental drug
Study: NCT03779919

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: extracorporeal shock wave
Description: Extracorporeal shock wave therapy uses acoustic waves to fragment calcific deposits. Variables of the settings include dose (low or high energy), duration (impulses), and the interval of administration.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: extracorporeal shock wave
Description: Extracorporeal shock wave therapy uses acoustic waves to fragment calcific deposits. Variables of the settings include dose (low or high energy), duration (impulses), and the interval of administration.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: extracorporeal shock wave
Description: Extracorporeal shock wave therapy uses acoustic waves to fragment calcific deposits. Variables of the settings include dose (low or high energy), duration (impulses), and the interval of administration.
Study: NCT04384393

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ThisCART19 cells
Description: 0.2-60 x 10\^6 CAR T cells per kg body weight.
Study: NCT03477513

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radation Therapy
Description: Personalized Radiation Therapy
Study: NCT01587339

Intervention type: DRUG
Intervention: retigabine/ezogabine
Description: oral - all doses

Intervention type: DRUG
Intervention: lacosamide
Description: oral - all doses

Intervention type: DRUG
Intervention: zonisamide
Description: oral - all doses

Intervention type: DRUG
Intervention: pregabalin
Description: oral - all doses

Intervention type: DRUG
Intervention: eslicarbazepine
Description: oral - all doses
Study: NCT04869254

Intervention type: OTHER
Intervention: Lower lymphocyte/ATG ratio

Intervention type: OTHER
Intervention: Higher lymphocyte/ATG ratio
Study: NCT00836251

Intervention type: DIETARY_SUPPLEMENT
Intervention: H218O and 2H2O, administered as a mixed cocktail
Description: 0.195 g of H218O and 0.117 g of 2H2O per kg of estimated total body water (TBW), administered as a mixed cocktail
Study: NCT01701076

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Induction treatment phase (cycle 1-6):~* Bendamustine 75 mg/m2 i.v day 1 and 2~* Lenalidomide 25 mg p.o. day 1-21~* Dexamethasone 40/20 mg p.o., day 1, 8, 15, 22~* Pegfilgrastim 6 mg s.c., day 3 in case of severe neutropenia~Maintenance treatment phase (cycles 7-18):~* Lenalidomide 25 mg p.o. day 1-21~* Dexamethasone 40/20 mg p.o., day 1, 8, 15, 22
Study: NCT01638078

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thalidomide
Description: Thalidomide, pill, 50 mg, once p.d., 6 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, pill, once p.d., 6 weeks
Study: NCT03819036

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Day 0 : Satisfaction questionnaire immediately after consultation Day 1, Day 3 and Day 7 : Telephone follow-up
Study: NCT01817283

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triptolide
Description: Triptolide Wilfordii is a Chinese old herb which is widely used as a remedy for rheumatic diseases and nephropathy in China. It is approved that it can play a role as an immune modular.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Triptolide
Description: Triptolide Wilfordii is a Chinese old herb which is widely used as a remedy for rheumatic diseases and nephropathy in China. It is approved that it can play a role as an immune modular.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cART
Description: Participants who will be enrolled in this trial would keep their previous combined antiretroviral therapy, such as zidovudine or stavudine plus lamivudine plus nevirapine or efavirenz.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: cART
Description: Participants who will be enrolled in this trial would keep their previous combined antiretroviral therapy, such as zidovudine or stavudine plus lamivudine plus nevirapine or efavirenz.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo pills produced the same as Triptolide wilfordii.
Study: NCT01091688

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Just-in-Time information
Description: Infants and physicians assigned to the intervention group will receive Just-in-Time information at the time of NICU discharge, by email and facsimile, and the parents will receive a copy to bring to their first clinic appointment.
Study: NCT01214863

Intervention type: DEVICE
Intervention: T3
Description: Implantation of the AcrySof Toric Intraocular Lens (IOL) Model SN60T3

Intervention type: DEVICE
Intervention: T4
Description: Implantation of the AcrySof Toric Intraocular Lens (IOL) Model SN60T4

Intervention type: DEVICE
Intervention: T5
Description: Implantation of the AcrySof Toric Intraocular Lens (IOL) Model SN60T5
Study: NCT00865904

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-809
Description: Capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-809
Description: Capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-809
Description: Capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-809
Description: Capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matched to VX-809 capsules.
Study: NCT02566577

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fresh red blood cell (RBC) transfusion
Description: 1 or 2 cross-matched, packed red blood cells (RBC) units from fresh (\<10 days old) blood, as ordered by the attending physician, will be given as an intravenous infusion via a programmable electronic infusion pump (Baxter, Inc) over a period of 1 hour per unit.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fresh red blood cell (RBC) transfusion
Description: 1 or 2 cross-matched, packed red blood cells (RBC) units from fresh (\<10 days old) blood, as ordered by the attending physician, will be given as an intravenous infusion via a programmable electronic infusion pump (Baxter, Inc) over a period of 1 hour per unit.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Storage-aged red blood cell (RBC) transfusion
Description: 1 or 2 cross-matched, packed red blood cells (RBC) units from storage-aged (\>21 days old) blood, as ordered by the attending physician, will be given as an intravenous infusion via a programmable electronic infusion pump (Baxter, Inc) over a period of 1 hour per unit.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Storage-aged red blood cell (RBC) transfusion
Description: 1 or 2 cross-matched, packed red blood cells (RBC) units from storage-aged (\>21 days old) blood, as ordered by the attending physician, will be given as an intravenous infusion via a programmable electronic infusion pump (Baxter, Inc) over a period of 1 hour per unit.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Electronic infusion pump
Description: A programmable, electronic infusion pump (Baxter, Inc) will be used for intravenous transfusion of units of packed red blood cells (RBC). The pump will be programmed to deliver 1 unit of packed RBC per hour.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Electronic infusion pump
Description: A programmable, electronic infusion pump (Baxter, Inc) will be used for intravenous transfusion of units of packed red blood cells (RBC). The pump will be programmed to deliver 1 unit of packed RBC per hour.
Study: NCT03353974

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Video game therapy
Description: Video game therapy will be delivered with a commercial video game console (X-Box 360 Kinect, Microsoft, Inc., Redmond, WA).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Balance platform therapy
Description: Balance/rebalancing, postural stability and weight-shifting exercises with and without visual feedback will be administered using a balance platform (Biodex Medical Systems, Inc., Shirley, NY).
Study: NCT03591354

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: t:slim X2 with Control-IQ Technology & Dexcom G6 CGM
Description: Participants will use the Tandem t:slim X2 insulin pump with Control-IQ Technology \& Dexcom G6 CGM for 3 months.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: t:slim X2 with Basal-IQ & Dexcom G6 CGM
Description: Participants will use a Tandem t:slim X2 insulin pump with Basal-IQ and a study CGM (Dexcom G6) for 3 months.
Study: NCT00572962

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: use of a tissue separating mesh (Proceed®) in Laparoscopic Ventral hernia repair
Description: use of a tissue separating mesh (Proceed®) in Laparoscopic Ventral hernia repair
Study: NCT04404322

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IPT A Suicide Crisis Intervention
Description: The intervention is comprised of five weekly sessions followed by monthly emails to the patients and their parents over a period of three months. The first session is aimed at introducing the intervention, assessing depression and suicidal risk and building a safety plan. The safety plan consists of a prioritized list of coping strategies that the patient can use when suicidal risk is increased. The second session is focused on reviewing the patient's interpersonal relationships (using the closeness circle and interpersonal inventory) and conceptualizing the interpersonal problem area. Sessions 3-4 focus on developing and practicing interpersonal, emotional and behavioral coping strategies relevant for suicidal risk. Lastly, in session 5, patient and therapist go over the process and main issues which were worked on, emphasizing relapse prevention by going back to the safety plan. First and fifth sessions always involve the parents.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment As Usual
Description: patients receive an integrative combination of psychodynamic, supportive and cognitive behavioral therapy, usually lasting between 10-30 weeks
Study: NCT04651543

Intervention type: OTHER
Intervention: X-Ray
Description: X-ray obtained at one-week of the fracture

Intervention type: OTHER
Intervention: X-Ray
Description: X-ray obtained at one-week of the fracture
Study: NCT03015519

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albiglutide
Description: 30 mg of lyophilized albiglutide will be delivered from a prefilled dual chamber glass cartridge (DCC). The pen injector system will deliver 0.5 mL albiglutide as a single subcutaneous injection once a week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albiglutide
Description: 30 mg of lyophilized albiglutide will be delivered from a prefilled dual chamber glass cartridge (DCC). The pen injector system will deliver 0.5 mL albiglutide as a single subcutaneous injection once a week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albiglutide
Description: 30 mg of lyophilized albiglutide will be delivered from a prefilled dual chamber glass cartridge (DCC). The pen injector system will deliver 0.5 mL albiglutide as a single subcutaneous injection once a week.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be delivered from a prefilled dual chamber glass cartridge DCC. The pen injector system will deliver 0.5 mL matching placebo as a single subcutaneous injection once a week.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be delivered from a prefilled dual chamber glass cartridge DCC. The pen injector system will deliver 0.5 mL matching placebo as a single subcutaneous injection once a week.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be delivered from a prefilled dual chamber glass cartridge DCC. The pen injector system will deliver 0.5 mL matching placebo as a single subcutaneous injection once a week.
Study: NCT02372916

Intervention type: DRUG
Intervention: Ranibizumab
Description: The medication Ranibizumab is routine standard of care for patients with wet AMD, and this is not an aspect of the study that is considered novel intervention

Intervention type: DRUG
Intervention: Ranibizumab
Description: The medication Ranibizumab is routine standard of care for patients with wet AMD, and this is not an aspect of the study that is considered novel intervention